Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy

Journal of Viral Hepatitis

Volumn 8, Issue 6, 2001, Pages 414-420

  McHutchison, J G ^a   Shad, J A ^a   Gordon, S C ^b   Morgan, T R ^c   Ling, M H ^d   Garaud, J J ^d   Albrecht, J K ^d   Dienstag, J L ^e  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

^c VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

HCV; HCV RNA; Interferon; Prediction of non response and response; Ribavirin

Indexed keywords

ALPHA2B INTERFERON; PLACEBO; RIBAVIRIN; VIRUS RNA;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FOLLOW UP; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; VIROLOGY;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; RNA, VIRAL; TIME FACTORS;

EID: 0035552139     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2001.00312.x     Document Type: Article

References (25)

1. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
2. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C
3. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
4. Therapy of hepatitis C. Interferon alfa-2a trials
5. Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial
6. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic C compared with recombinant interferon alfa-2b: Results of an international randomized controlled trial
7. Treatment of chronic hepatitis C with recombinant alpha-interferon: A multi-center randomized, controlled trial
8. Randomized trial of interferon alfa-2b plus placebo for 48 weeks for treatment of chronic hepatitis C virus
9. Is an 'a la carte' combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?
10. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy
11. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: A comparison
12. Discordance between serum alanine amino-transferase (ALT) and virologic response to IFN-alpha 2b in chronic hepatitis C patients with high and low pretreatment serum hepatitis C virus RNA titers
13. Is there an optimal time to measure quantitative HCV RNA to predict non-response during interferon treatment for chronic HCV infection
14. Ultracentrifugation and concentration of a large Volume of serum for HCV RNA during treatment may predict sustained and relapse response in chronic HCV infection
15. Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C
16. Correlatioon of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin
17. Prolonged therapy of chronic hepatitis C with ribavirin
18. Ribavirin treatment for patients with chronic hepatitis C. Results of a placebo-controlled study
19. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C. A multicenter trial
20. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C
21. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses
22. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinases and preserves Th1 cytokine production but inhibits Th2 cytokine response
23. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C. A dynamic view
24. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C